Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: A systematic review and meta-analysis

Journal of Public Health Research

Volumn 5, Issue 3, 2016, Pages 130-138

  Badawi, Alaa ^a   Ryoo, Seung Gwan ^b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

2009 influenza A (H1N1); Diabetes mellitus; Systematic review; The middle east respiratory syndrome coronavirus (MERS CoV)

Indexed keywords

2009 H1N1 INFLUENZA; ARTICLE; COMORBIDITY; DATA EXTRACTION; DIABETES MELLITUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; OBESITY; PREVALENCE; QUALITY CONTROL; SYSTEMATIC REVIEW;

EID: 85007599853     PISSN: 22799028     EISSN: 22799036     Source Type: Journal    
DOI: 10.4081/jphr.2016.733     Document Type: Article

References (89)

1. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modeling study. Lancet Infect Dis 2012; 12: 687-95.
2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). 2015. Available from: http://www.who.int/emergencies/mers-cov/en/ (accessed on October 29, 2015).
3. Al-Soub H, Ibrahim AS, Al-Maslamani M, et al. Epidemiology, risk factors, clinical features, and outcome of adult patients with severe pandemic A/H1N1/2009 influenza in Qatar: a retrospective study. Infect Dis Clin Pract 2014; 22: 339-43.
4. Allam RR, Murhekar MV, Tadi GP, Udaragudi PR. Descriptive epidemiology of novel influenza A (H1N1), Andhra Pradesh 2009-2010. Ind J Pub Health 2013; 57: 161-5.
5. Chawla R, Kansal S, Chauhan M, et al. Predictors of mortality and length of stay in hospitalized cases of 2009 influenza A (H1N1): Experiences of a tertiary care center. Ind J Crit Care Med 2013; 17: 275-82.
6. Arabi YM, Arifi AA, Kalkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160: 389-97.
7. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrom coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis 2013; 13: 752-61.
8. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369: 407-16.
9. Al-Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndrome coronavirus: A case-control study of hospitalized patients. Clin Infect Dis 2014; 59: 160-5.
10. Cunha CB, Opal SM. Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia. Virulence 2014; 5: 650-4.
11. Wang C, Yu E, Xu B, et al. Epidemiological and clinical characteristics of the outbreak of 2009 pandemic influenza A (H1N1) at a middle school in Luoyang, China. Public Health 2012; 126: 289-94.
12. Casqueiro J, Casquerio J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Ind J Endocrinol Metabol 2012; 16: S27-36.
13. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007; 50: 549-54.
14. Cortes Garcia M, Moros MJS, Perlta PSO, et al Clinical characteristics and outcomes of diabetic patients who were hospitalized with 2009 pandemic influenza A H1N1 infection. J Infection 2012; 64: 218-24.
15. Bagshaw SM, Sood MM, Long J, et al. Acute kidney injury among critically ill patients with pandemic H1N1 influenza A in Canada: a cohort study. BMC Nephrol 2013; 14: 123.
16. Balaganesakumar SR, Murhekar MV, Swamy KK, et al. Risk factors associated with death among influenza A (H1N1) patients, Tamil Nadu, India, 2010. J Postgrad Med 2013; 59: 9-14.
17. Jimenez-Garcia R, Hernandez-Barrera V, Rodriguez-Rieiro C, et al. Hospitalizations from pandemic influenza [A(H1N1)pdm09] infections among type 1 and 2 diabetes patients in Spain. Influ Other Resp Viruses 2013; 7: 439-47.
18. Kusznierz G, Uboldi A, Sosa G, et al. Clinical features of the hospitalized patients with 2009 pandemic influenza A (H1N1) in Santa Fe, Argentina. Influ Other Resp Viruses 2013; 7: 410-7.
19. Suryaprasad A, Redd JT, Hancock K, et al. Severe acute respiratory infections caused by 2009 pandemic influenza A (H1N1) among American Indians: southwestern United States, May 1-July 21, 2009. Influnza Other Resp Viruses 2013; 7: 1361-9.
20. Vallejos A, Arias M, Cusumano A, et al. Dialysis for acute kidney injury associated with influenza A (H1N1) infection. Saudi J Kidney Dis Transpl 2013; 24: 527-33.
21. Aziz-Baumgartner E, Cabrera AM, Chang L, et al. Mortality, severe acute respiratory infection, and influenza-like illness associated with influenza A(H1N1)pdm09 in Argentina, 2009. PLoS One 2012; 7: e47540.
22. Chowell G, Echevarria-Zuno S, Viboud C, et al. Epidemiological characteristics and underlying risk factors for mortality during the autumn 2009 pandemic wave in Mexico. PLoS One 2012; 7: e41069.
23. Delgada-Rodriguez M, Castilla J, Gordoy P, et al. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. Antimicrob Chrmother 2012; 67: 1739-45.
24. Marija Kojicic P, Kovacevic N, Batranovic J, et al. Characteristics and outcome of mechanically ventilated patients with 2009 H1N1 influenza in Bosnia and Herzegovina and Serbia: impact of newly established multidisciplinary intensive care units. Croat Med J 2012; 53: 620-6.
25. Miller AC, Subramanian RA, Safi F, et al. Influenza A 2009 (H1N1) virus in admitted and critically ill patients. J Intensive Care Med 2012; 27: 25-31.
26. Wane J, Nytanyi T, Nkunda R, et al. Pandemic influenza (H1N1) virus outbreak and response - Rwanda, October, 2009-May, 2010. PLoS One 2012; 7: e31572.
27. Chudasama RK, Patel UV, Verma PB, et al. Clinico-epidemiological features of the hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in Saurashtra region, India (September, 2009 to February, 2010). Lung Ind 2011; 28: 11-5.
28. Gilca R, Serres GD, Boulianne N, et al. Risk Factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. Influenza Other Respir Viruses 2011; 5: 247-55.
29. Ward KA, Spokes PJ, McAnulty JM. Case-control study of risk factors for hospitalization caused by pandemic (H1N1) 2009. Emerg Infect Dis 2011; 17: 1409-16.
30. Yokota RTC, Skalinski LM, Igansi CN, et al. Risk factors for death from pandemic (H1N1) 2009, Southern Brazil. Emerg Infect Dis 2011; 17: 1467-71.
31. Van Kerkhove MD, Vandemaele KAH, Shinde V, et al. Risk factors for severe outcomes following 2009 Influenza A (H1N1) infection: A global pooled analysis. PLoS Med 2011; 8: e1001053.
32. Allard R, Tremblay C, Leclerc P, Tannunbaum TN. Diabetes and the severity of pandemic Influenza A (H1N1) infection. Diab Care 2010; 33: 1491-3.
33. Carcione D, Giele C, Dowse GK, et al. Comparison od pandemic (H1N1) 2009 and seasonal influenza, Western Australia, 2009. Emerg Infect Dis 2010; 16: 1388-95.
34. Fajardo-Dolci G, Gutierrez-Vega R, Arboleya-Casanova H, et al. Clinical characteristics of fatalities due to influenza A (H1N1) virus in Mexico. Thorax 2010; 65: 505-9.
35. Koegelenberg CFN, Irusen EM, Cooper R, et al. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. QJ Med 2010; 103: 319-25.
36. Venkata C, Sampathkumar P, Afessa B. Hospitalized patients with 2009 H1N1 influenza infection: the Mayo clinic experience. Mayo Clin Proc 2010; 85: 798-805.
37. Xi X, Jiang L, Li A, et al. Hospitalized adult patients with 2009 influenza A (H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis 2010; 10: 256.
38. Centers for Disease Control and Prevention. Death related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives - 12 States, 2009. Morbidity and Mortality Weekly Report MMWR 2009; 58: 1341-4.
39. Kwan-Gett TS, Baer A, Duchin JS. Spring 2009 H1N1 influenza outbreak in King County, Washington. Disaster Med Public Health Prepared 2009; 3: S109-16.
40. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-2a or IFN-1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. Antimicrob Chemother 2015; 70: 2129-32.
41. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20: 42-6.
42. Memish ZA, Cotton M, Watson SJ, et al. Community case cluster of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis 2014; 23: 63-8.
43. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 2013; 369: 884-6.
44. The WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East Respiratory syndrome coronavirus (MERSCoV) in humans. PLOS Currents Outbreaks 2013; 1.
45. Cohen A. Comparison of correlated correlations. Stat Med 1989; 8: 1485-95.
46. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
47. Badawi A, Arora P, Sadoun E, et al. Prevalence of vitamin D insufficiency in Qatar: a systematic review. J Publ Health Res 2012; 1: 229-35.
48. Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as a computational backend. J Stat Software 2012; 49: 1-15.
49. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
50. Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539-58.
51. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
52. Guleria R, Kuma J, Mohan A, Wig N. Influenza A: From highly pathogenic H5N1 to pandemic 2009 H1N1. Epidemiology and clinical features. Ind J Microbiol 2009; 49: 315-9.
53. Newman AP, Residorf E, Beinemann J, et al. Human case of swine influenza A (H1N1) triple reassortant virus infection, Wisconsin. Emerg Infect Dis 2008; 14: 1470-2.
54. Veljkovic V, Niman HL, Glisic S, et al. Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor. BMC Structural Biol 2009; 9: 62.
55. Milne-Price S, Miazgowicz KL, Munster VJ. The emergence of the Middle East Respiratory Syndrome coronavirus. Pathogens Dis 2014; 71: 121-36.
56. Khalafalla AI, Lu X, Al-Mubarak AIA, et al. MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg Infect Dis 2015; 12: 1153-8.
57. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19: 1819-23.
58. Cauchemez S, Fraser C, Van Kerkhove MD, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 2014; 14: 50-6.
59. Korea Centers for Disease Control and Prevention. Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015. Osong Pub Health Res Perspect 2015; 6: 269-78.
60. Gardner LM, MacIntyre CR. Unanswered questions about the Middle East respiratory syndrome coronavirus (MERS-CoV). BMC Res Notes 2014; 7: 358.
61. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358: 261-73.
62. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945-52.
63. Kok J, Dwyer DE. How common was 2009 pandemic influenza A H1N1? Lancet Infect Dis 2011; 11: 423-4.
64. Tumpey TM, Garcia-Sastre A, Taubenberger JK, et al. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci 2004; 101: 3166-71.
65. Davenport FM, Hennessay AV, Francis T. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Experl Med 1953; 98: 641-56.
66. Fowler RA, Kumar A, Christian M, Martin CM. Guidance for the management of severe acute respiratory infection in the intensive care unit. Canadian Critical Care Society 2013. Available from: http://www.canadiancriticalcare.org/website/Guidelines/CCCS%20SARI%20guidance%20January%202014.pdf.
67. Mokdad AH, Jaber S, Abdel Aziz MI, et al. Burden of disease, injuries, and risk factors in the Arab World 1990-2010. Lancet 2014; 383: 62189-3.
68. Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743-800.
69. Al-Mahroos F, Al-Roomi K. Overweight and obesity in the Arabian Peninsula: an overview. J R Soc Promot Health 1999; 119: 251-3.
70. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and metaanalysis. BMJ 2013; 347: f5061.
71. Choi BC, Shi F. Risk factors for diabetes mellitus by age and sex: results of the National Population Health Survey. Diabetologia 2001; 44: 1221-31.
72. Alhyas L, McKay A, Majeed A. Prevalence of type 2 diabetes in the States of the co-operation council for the Arab States of the Gulf: a systematic review. PLoS One 2012; 7: e40948.
73. Badawi, A, Sayegh S, Sallam M, et al. The global relationship between the prevalence of diabetes mellitus and incidence of tuberculosis: 2000-2012. Glob J Healt Sci 2015; 7: 183-91.
74. International Diabetes Federation. Diabetes Atlas, Sixth Edition, 2013. IDF 2013. Available from: http://www.diabetesatlas.org.
75. Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes 2010; 3: 173-86.
76. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9: 737-46.
77. Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. Acta Diabetol 2001; 38: 77-82.
78. Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep 2010; 12: 448-55.
79. Toledo J, George L, Martinez E, et al. Relevance of non-communicable comorbidities for the development of the severe forms of dengue: a systematic literature review. PLoS Negl Trop Dis 2016; 10: e0004284.
80. Kesavadev J, Misra A, Das AK, et al. Suggested use of vaccines in diabetes. Ind J Endocrinol Metab 2012; 16: 886-93.
81. Arora P, Garcia-Bailo B, Dastani, Z, et al. Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes. BMC Med Genetics 2011; 12: 95.
82. American Diabetes Association. Influenza and Pneumococcal Immunization in Diabetes. Diabet Care 2004; 27: S111-3.
83. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report MMWR 2006; 55: 1-41.
84. Burney LE. Influenza immunization: statement. Public Health Rep 1960; 75: 944.
85. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59: 1-62.
86. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med 2015; 13: 53.
87. American Diabetes Association. Standards of medical care - 2007. Diabet Care 2007; 30: S4-42.
88. Schaffner W, Rehm SJ, Elasy TA. Influenza vaccination: an unmet need in patients with diabetes. Clin Diabet 2007; 25: 145-9.
89. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage among persons aged ≥65 years and persons aged 18-64 years with diabetes or asthma - United States, 2003. Morbidity and Mortality Weekly Report MMWR 2004; 53: 1007-15.